RESUMEN
Introduction: Expression and certain SNPs of interferon lambda 3 and 4 (IFNL3 and 4) have been associated with variable outcomes in COVID-19 patients in different regions, suggesting population-specific differences in the disease outcome. This study examined the association of INFL3 and INFL4 SNPs (rs12979860 and rs368234815, respectively) and nasopharyngeal expression with COVID-19 disease severity in Pakistani patients. Methods: For this study, 117 retrospectively collected nasopharyngeal swab samples were used from individuals with mild and severe COVID-19 disease. qPCR assays were used to determine the viral loads and mRNA expression of IFNL3 and 4 through the Ct and delta Ct methods, respectively. Due to funding limitations, only one SNP each in INFL3 and INFL4 (found to be most significant through literature search) was analyzed using tetra-arm PCR and RFLP-PCR strategies, respectively. The Mann-Whitney U-test was applied to evaluate the statistical differences in the expression of IFNL3/4 genes in the mild and severe groups, while for SNPs, a Chi-square test was employed. A multivariate Cox regression test was performed to assess the relationship of different variables with COVID-19 severity. Results: Comparative analysis of SNPs between mild and severe groups showed only the difference in SNP of the IFNL4 gene to be statistically significant (p = 0.001). Similarly, nasopharyngeal expression of IFNL3 and IFNL4 genes, respectively, was found to be 3.48-fold less and 3.48-fold higher in the severe group as compared to the mild group. Multivariate analysis revealed SNP in the IFNL4 gene and age to have a significant association with COVID-19 severity. Conclusion: Despite the small sample size, IFNL4 gene SNP and patient age were associated with COVID-19 severity. Age, IFNL3/IFNL4 mRNA expression in the nasopharyngeal milieu, and the presence of SNP in the IFNL4 (rs368234815) gene in COVID-19 patients may be biomarkers for infection severity and help improve SARS-CoV-2 infection management.
RESUMEN
INTRODUCTION: A subset of individuals with COVID-19 can suffer from a severe form of the disease requiring breathing support for respiratory failure and even death due to disease complications. COVID-19 disease severity can be attributed to numerous factors, where several studies have associated changes in the expression of serum pro-inflammatory cytokines with disease severity. However, very few studies have associated the changes in expression of pro-inflammatory changes in the nasopharyngeal milieu with disease severity. Therefore, in the current study, we performed differential gene expression analysis of various pro-inflammatory cytokines in the nasopharyngeal milieu of mild & severe COVID-19 cases. MATERIAL AND METHOD: For this retrospective, cross-sectional study, a total of 118 nasopharyngeal swab samples, previously collected from mild and severe (based on the WHO criteria) COVID-19 patients were used. A real-time qPCR was performed to determine the viral loads and also evaluate the mRNA expression of eight cytokines (IL-1, IL-2, IL-4, IL-6, IL-10, IFN-γ, TGF-ß1, and TNF-α). Subsequently, an unpaired T-test was applied to compare the statistical difference in mean expression of viral loads and each cytokine between the mild and severe groups, while the Pearson correlation test was applied to establish a correlation between disease severity, viral load, and cytokines expression. Similarly, a multivariable logistic regression analysis was performed to assess the relationship between different variables from the data and disease severity. RESULTS: Out of 118 samples, 71 were mild, while 47 were severe. The mean viral load between the mild and severe groups was comparable (mild group: 27.07± 5.22; severe group: 26.37 ±7.89). The mRNA expression of cytokines IL-2, IL-6, IFN- γ, and TNF-α was significantly different in the two groups (p<0.05), where the Log2 normalized expression of IL-2, IL-6, IFN- γ, and TNF-α was found to be 2.2-, 16-, 2.3-, and 1.73-fold less in the severe group as compared to the mild group. Furthermore, we also observed a significant positive correlation between all the cytokines in the severe group. The multivariate analysis showed a significant relationship between age, IL-6, and disease severity. CONCLUSION: This decreased expression of certain cytokines (IL-2, IL-6, TNF-α, and IFN-γ) in the nasopharyngeal milieu may be considered early biomarkers for disease severity in COVID-19 patients.
Asunto(s)
COVID-19 , Citocinas , Humanos , Citocinas/metabolismo , Factor de Necrosis Tumoral alfa/genética , Interleucina-6 , Interleucina-2/genética , Estudios Retrospectivos , Estudios Transversales , COVID-19/genética , Expresión Génica , Nasofaringe/metabolismo , ARN Mensajero/genéticaRESUMEN
Overexpression of epidermal growth factor receptor (EGFR) is commonly reported in epithelial malignancies such as oral squamous cell carcinoma. Inhibition of EGFR is, therefore, considered a potential therapeutic strategy. Among various anti-EGFR drugs, quinazoline-based tyrosine kinase inhibitors (TKIs) have gained increasing attention. Present study focused to investigate anti-EGFR potential of quinazoline-based compounds using in silico approach. Two widely used docking programs GOLD and AutoDock Vina were used for the study. Four drugs were docked on the X-ray crystallographic EGFR structure (1XKK). GOLD and AutoDock Vina produced results in terms of fitness score and binding affinity, respectively. GOLD prioritized varlitinib and AutoDock Vina preferred imatinib over other drugs. To reach the consensus from both software, all four drugs coupled with EGFR were studied rigorously. GOLD demonstrated varlitinib to be the best inhibitor with highest fitness score of 109, whereas AutoDock Vina revealed imatinib as the potent ligand with least binding energy of -10.9 kcal/mol. Most stable hydrogen bonds observed by GOLD and maximum number of hydrophobic contacts along with strong ionic interaction exhibited by varlitinib through both software have led us to conclude varlitinib as the most potent EGFR inhibitor in the studied group.
Asunto(s)
Carcinoma de Células Escamosas , Neoplasias de la Boca , Humanos , Mesilato de Imatinib , Ligandos , Simulación del Acoplamiento Molecular , Inhibidores de Proteínas Quinasas/química , Inhibidores de Proteínas Quinasas/farmacología , Quinazolinas/química , Quinazolinas/farmacologíaRESUMEN
BACKGROUND: Matrix metalloproteinases (MMPs) catalyzes the degradation of the extracellular matrix components and have a major role in many physiological processes including wound healing. In the current study, we examined the correlation of baseline MMPs 1, 2, 7, and 9 expressions with periapical wound healing after surgical endodontic treatment. METHODS: 27 patients aged between 15 and 57 years presenting with chronic apical periodontitis or chronic apical abscess of an anterior tooth with previously attempted or failed root canal treatment were included in this study. During surgical endodontic treatment, tissue from the periapical lesion sample was collected and used for gross histopathological analysis as well as mRNA expression analysis of MMPs 1, 2, 7, and 9. Patients were recalled for follow-up after 6 months to evaluate the healing status both clinically and radiographically and healing was correlated with baseline MMP expression. RESULTS: Out of 27 patients, healing was observed in 15 patients at the end of 6 months, and in 21 patients after 12 months.. Six patients showed no healing even after 12 months. Analysis of baseline MMP 1, 2, 7, and 9 expression levels with healing status showed the mean relative expression of MMP2 and MMP9 to be considerably increased in the non-healing group as compared to the healing group. CONCLUSION: Overexpression of MMP2 and MMP9 may be considered as a potential prognostic biomarker for periapical wound healing after surgical endodontic treatment. However, further studies are desirable to establish its precise relationship with periapical wound healing.
Asunto(s)
Granuloma Periapical , Periodontitis Periapical , Adolescente , Adulto , Humanos , Metaloproteinasas de la Matriz/genética , Persona de Mediana Edad , Granuloma Periapical/cirugía , Periodontitis Periapical/cirugía , Tratamiento del Conducto Radicular/efectos adversos , Cicatrización de Heridas , Adulto JovenRESUMEN
Genotype variation in viruses can affect the response of antiviral treatment. Several studies have established approaches to determine genotype-specific variations; however, analyses to determine the effect of these variations on drug-protein interactions remain unraveled. We present an in-silico approach to explore genotype-specific variations and their effect on drug-protein interaction. We have used HCV NS3 helicase and fluoroquinolones as a model for drug-protein interaction and have investigated the effect of amino acid variations in HCV NS3 of genotype 1a, 1b, 2b and 3a on NS3-fluoroquinolone interaction. We retrieved 687, 667, 101 and 248 nucleotide sequences of HCV NS3 genotypes 1a, 1b, 2b, and 3a, respectively, and translated these into amino acid sequences and used for genotype variation analysis, and also to construct 3D protein models for 2b and 3a genotypes. For 1a and 1b, crystal structures were used. Drug-protein interactions were determined using molecular docking analyses. Our results revealed that individual genotype-specific HCV NS3 showed substantial sequence heterogeneity that resulted in variations in docking interactions. We believe that our approach can be extrapolated to include other viruses to study the clinical significance of genotype-specific variations in drug-protein interactions.
Asunto(s)
Sitios de Unión/genética , Interacciones Farmacológicas/genética , Variación Genética/genética , Hepacivirus/efectos de los fármacos , Hepacivirus/genética , Secuencia de Aminoácidos , Aminoácidos/genética , Antivirales/farmacología , Simulación por Computador , Fluoroquinolonas/farmacología , Genotipo , Hepatitis C/tratamiento farmacológico , Hepatitis C/virología , Humanos , Simulación del Acoplamiento Molecular , Proteínas no Estructurales Virales/genéticaRESUMEN
BACKGROUND: Hepatitis C Virus (HCV) infection is a major public health concern across the globe. At present, direct-acting antivirals are the treatment of choice. However, the long-term effect of this therapy has yet to be ascertained. Previously, fluoroquinolones have been reported to inhibit HCV replication by targeting NS3 protein. Therefore, it is logical to hypothesize that the natural analogs of fluoroquinolones will exhibit NS3 inhibitory activity with substantially lesser side effects. METHOD: In this study, we tested the application of a recently devised integrated in-silico Cheminformatics-Molecular Docking approach to identify physicochemically similar natural analogs of fluoroquinolones from the available databases (Ambinter, Analyticon, Indofines, Specs, and TimTec). Molecular docking and ROC curve analyses were performed, using PatchDock and Graphpad software, respectively, to compare and analyze drug-protein interactions between active natural analogs, Fluoroquinolones, and HCV NS3 protein. RESULT: In our analysis, we were able to shortlist 18 active natural analogs, out of 10,399, that shared physicochemical properties with the template drugs (fluoroquinolones). These analogs showed comparable binding efficacy with fluoroquinolones in targeting 32 amino acids in the HCV NS3 active site that are crucial for NS3 activity. Our approach had around 80 % sensitivity and 70 % specificity in identifying physicochemically similar analogs of fluoroquinolones. CONCLUSION: Our current data suggest that our approach can be efficiently applied to identify putative HCV drug inhibitors that can be taken for in vitro testing. This approach can be applied to discover physicochemically similar analogs of virtually any drug, thus providing a speedy and inexpensive approach to complement drug discovery and design, which can tremendously economize on time and money spent on the screening of putative drugs.
Asunto(s)
Antivirales/metabolismo , Descubrimiento de Drogas/métodos , Inhibidores Enzimáticos/metabolismo , Fluoroquinolonas/metabolismo , Proteínas no Estructurales Virales/antagonistas & inhibidores , Antivirales/química , Dominio Catalítico , Quimioinformática , Inhibidores Enzimáticos/química , Fluoroquinolonas/química , Hepacivirus/enzimología , Simulación del Acoplamiento Molecular , Unión Proteica , Proteínas no Estructurales Virales/química , Proteínas no Estructurales Virales/metabolismoRESUMEN
BACKGROUND: In the current study, we present an integrated in silico cheminformaticsmolecular docking approach to screen and test potential therapeutic compounds against viruses. Fluoroquinolones have been shown to inhibit HCV replication by targeting HCV NS3-helicase. Based on this observation, we hypothesized that natural analogs of fluoroquinolones will have similar or superior inhibitory potential while having potentially fewer adverse effects. METHODS: To screen for natural analogs of fluoroquinolones, we devised an integrated in silico Cheminformatics-Molecular Docking approach. We used 17 fluoroquinolones as bait reference, to screen large databases of natural analogs. 10399 natural compounds and their derivatives were retrieved from the databases. From these compounds, molecules bearing physicochemical similarities with fluoroquinolones were analyzed using a cheminformatics-docking approach. RESULTS: From the 10399 compounds screened using our cheminformatics approach, only 20 compounds were found to share physicochemical similarities with fluoroquinolones, while the remaining 10379 compounds were physiochemically different from fluoroquinolones. Molecular docking analysis showed 32 amino acids in the HCV NS3 active site that were most frequently targeted by fluoroquinolones and their natural analogues, indicating a functional similarity between the two groups of compounds. CONCLUSION: This study describes a speedy and inexpensive approach to complement drug discovery and design against viral agents. The in silico analyses we used here can be employed to shortlist promising compounds/putative drugs that can be further tested in wet-lab.
Asunto(s)
Antivirales/farmacología , Quimioinformática/métodos , Descubrimiento de Drogas/métodos , Fluoroquinolonas/química , Hepacivirus/efectos de los fármacos , Simulación del Acoplamiento Molecular , Antivirales/aislamiento & purificación , Productos Biológicos/química , Productos Biológicos/farmacología , Quimioinformática/economía , Descubrimiento de Drogas/economía , Fluoroquinolonas/farmacología , Ensayos Analíticos de Alto RendimientoRESUMEN
The safe disposal of industrial effluents always remained a challenging process because of their high level of nutrients, toxic elements, and salts. A pot experiment was conducted to investigate the effects of various concentrations (5%, 10%, 15%, and 20%) of sugar industry effluent spentwash (SW) fertigated with tab water (TW), on soil properties, crop growth, physiological parameters, yield components, and accumulation of potentially toxic elements (PTEs) in rice (Oryza sativa L.) grains and straw. The results showed that soil physico-chemical properties were modified with rise in SW concentration. Application of 5% SW significantly enhanced the plant growth, and yield components. Photosynthesis rate, transpiration rate, and stomatal conductance were significantly higher under 5% SW concentration in comparison with control. However, SW concentrations of > 5% showed inhibitory effects for all growth, physiological, and yield components. Accumulation of PTEs showed increasing trend with rise in SW concentration. However, under 5% SW concentration, all the PTEs in rice grain and straw were within the permissible limits (PLs) recommended by FAO/WHO and no health hazards were detected by health risk assessment. Based on the study results, 5% SW fertigation with TW can be applied as fertilizer for enhancing the growth and productivity of rice. Graphical abstract.
Asunto(s)
Fertilizantes , Oryza , Azúcares , Residuos , Grano Comestible/crecimiento & desarrollo , Grano Comestible/metabolismo , Oryza/crecimiento & desarrollo , Oryza/metabolismo , Suelo/química , Contaminantes del Suelo/metabolismoRESUMEN
Helicase enzyme is responsible for the unwinding of complementary nucleic acid strands, which is one of the preliminary steps in DNA replication. They are crucial for replication of an organism, including viruses. HCV and HIV are two clinically significant pathogens, responsible for millions of infections and deaths worldwide. Due to similar transmission routes, these viruses can establish co-infection in an individual. Individually, these infections are difficult to treat, however, in case of co-infection, the treatment becomes more difficult. Additionally, these viruses accumulate mutation in response to drug therapy that renders the treatment ineffective. HCV and HIV both encode enzyme containing helicase activity. The viral-encoded helicase plays a significant role in HIV and HCV life cycle. Here we propose viral helicases as an ideal single-hit target that can inhibit HIV and HCV co-infection. We also hypothesize that search for natural analogs sharing basic ring structure with a class of helicase inhibitors called fluoroquinolones can yield natural agents with superior antiviral (anti-helicase) activity with lower toxicity index. The fluoroquinolones and their analogs are currently not part of any antiviral regimens. Our proposal is to include fluoroquinolones-derived natural analogs as a conjugate therapy along with main regimens available against HCV and HIV co-infection.